Adtec SteriPlas for the treatment of deep sternal wound infections and infected drivelines
The Adtec SteriPlas has already been well documented for the treatment of deep sternal wound infections and infected drivelines. Separate studies from two leading hospitals in Germany (University Hospital Munster and University Hospital Heidelberg) have recorded the strong efficacy of our cold plasma treatment on these problematic conditions. Due to the original difficulty of managing these chronic infections using standard therapies along with the high rate of morbidity and mortality, it is no wonder why the Adtec SteriPlas has been chosen as the preferred treatment method.
You can read more about its story in the latest addition of the Chirurgische Allgemeine magazine: eSD_AdTecPlasma
New SteriPlas version and change in device Classification
Due to our proven clinical success in treating non-healing and challenging wounds, we are proud to announce the upgrade of our medical device classification to Class IIb for the Adtec SteriPlas .
This change in medical device classification also supports its continued use for treating chronic and deep wounds and surgical site infections and for treating dermatological conditions.
We also announce the product launch of a new version of our SteriPlas Version 2 model in our Cold Plasma medical device family delivering the same performance. We are very proud of the safety of our devices with no incidents or adverse events reported in 15 years of use.
SteriPlas treatment for Acne Vulgaris
We are excited to announce the recent publication, “Cold atmospheric plasma (CAP) as a promising therapeutic option for mild to moderate acne vulgaris” which features our Adtec SteriPlas cold plasma for the treatment of acne.
The paper created by Dr Mariachiara Arisi from the Department of Dermatology at the University of Brescia, Italy demonstrates the antibacterial efficacy of our patented cold plasma for the treatment of acne vulgaris patients. It indicates the significant reduction of acne skin lesions in treated patients who were previously unsuccessful treated with topical drugs. Unlike topical drugs, the Adtec SteriPlas demonstrated a safe, effective, and well-tolerated treatment option with no side effects for the treatment of acne patients.
No adverse effects or skin reactions were reported either during the treatment nor at 3-months follow-up. Treatment was completely painless and well tolerated. Patients did not report itching or burning sensation during plasma application and in the following days.
The full paper can be found here: https://www.sciencedirect.com/science/article/pii/S2212816620300172
Adtec Healthcare's new project with Hull York Medical School testing gas plasma on Osteomyelitis bone infections.
We are excited to announce the study “Gas Plasma for the Prevention and Management of Osteomyelitis Biofilms” has now begun at the Hull York Medical School. The study led by Dr Angela Oates and funded by the National Biofilms Innovation Centre will seek to test the efficacy of our gas plasma system on osteomyelitis bone infections using our PlasmaTact device. This project will develop a novel laboratory testing model to evaluate and optimise plasma treatment for osteomyelitis biofilm infections.
We have already demonstrated that our gas plasma medical device, the Adtec SteriPlas, has proven antibacterial efficacy and accelerated healing in problematic and non-healing wounds with strong evidence collected from our extensive library of clinical trials and publications. This includes diabetic foot ulcers which are often complicated by biofilm. Over the course of its existence it has shown that no side effects have been reported which offers patients a safe and reliable treatment option. It has also shown that a 2-minute treatment time is sufficient to achieve exceptional results and that it is also a broad spectrum antibacterial with the ability to kill a wide range of Gram-negative and Gram-positive bacterial superinfections.
The PlasmaTact utilizes the same gas plasma technology from the Adtec SteriPlas. The main difference between the two devices is that the PlasmaTact offers a smaller handheld style treatment area of 1cm2 (vs 12cm2 with the SteriPlas) and offers users the ability to change the power output settings (vs the fixed settings with the SteriPlas).
Osteomyelitis (OM) is biofilm infection of the bone and is a common and costly complication in diabetic foot ulcer (DFU) patients often resulting in amputations. Long-term antimicrobial therapy is widely used as a primary treatment for OM or as an adjunct to surgical approaches however, there is a failure rate of up to 35% and an associated increasing prevalence of antimicrobial resistance. There is an urgent clinical need to develop alternative non-antimicrobial approaches to treat infections, and currently there is a lack of credible alternatives in the market for the treatment of OM.
Evaluating the efficacy of gas plasma in OM represents unique challenges as both the biofilm growth and physical characteristics of OM bone will affect the delivery and activity of the plasma. In vitro biofilm model systems offer a means by which rapid, costs effective and standardised evaluation of anti-biofilm treatments can be undertaken.
The PATROL project is a new and exciting collaborative project between Adtec Healthcare and Dr Angela Oates of the University of Hull Wound Healing Group which is supported by NBIC PoC Award. The overall aim of this project is to develop an osteomyelitis biofilm infection model to support the optimisation and evaluation of a cold plasma technology for the management and prevention of OM.
This collaborative project represents the first phase of the novel utilisation of Adtec SteriPlas to treat OM or as an adjunct current therapy. Successful translation of this technology to treat OM will reduce antimicrobial usage and associated OM amputations, reducing NHS costs and ultimately improving patient outcomes.
#osteomyelitis #biofilm #boneinfection #infection #antimicrobial #antimicrobialresistance #amputation #plasma #gasplasma #coldplasma #kaltesplasma #NBIC #universityofhull #podiatry #diabeticfootulcer #diabeticfoot #diabetes #hullyorkmedicalschool
EWMA
We had a great time exhibiting at the EWMA 2019 conference. We would like to congratulate Maurice Moelleken, Dr Heinrich Rotering and Dr Michael Pierides for their brilliant presentations during the conference. Their data showed the strong benefits of using the Adtec SteriPlas on chronic wounds and surgical site infections, offering an alternative to standard treatment therapies that bacteria may pose a resistance to.
The Adtec SteriPlas has proven antibacterial efficacy backed by a wide clinical bibliography and no side effects reported making it safe, painless and effective for the treatment of infected wounds stalled by bacteria.
For more information send us an email to info@adtec.eu.com
#EWMA #EWMA2019 #antimicrobialresistance #medicaldevice
#gasplasma #coldplasma #kaltesplasma
Poster presentation at the International Symposium on the Diabetic Foot Conference, Hague.
Wednesday 22nd May 2019
A great poster presentation from Dr Aye Aye Thant at the ISDF 2019 conference!
Dr Thant’s presentation demonstrated the benefits of using the Adtec SteriPlas on diabetic foot ulcer patients.
Prior to the use of the Adtec SteriPlas, all patients in their retrospective study suffered from chronic and non-healing foot and leg ulcers with multi resistant bacteria and recalcitrance to antibiotics. All patients had at least 3 courses of intravenous antibiotics for more than 6 weeks prior with poor response.
The Adtec SteriPlas was then introduced as a treatment option. Instantly, positive results could be seen with the infection management for these patients. For example, one patient who was previously considered for an amputation was now improved and risk free. Healthy granulation could be observed with all patients, offering hope and an alternative to antibiotics that would usually be offered.
For more information on the Adtec SteriPlas, visit our website www.adtecplasma.com or send us an email at info@adtec.eu.com
Mr Keith Cutting presents significant results on DFUs in Vienna conference
Mr Keith Cutting presented at The European Conference on Controversies in Diabetic Foot Management conference in Vienna last week. His presentation focused on the benefits of treating complex diabetic foot ulcer patients with the Adtec SteriPlas.
The Adtec SteriPlas has shown promising results leading to healing in problematic and non-healing wounds such as diabetic foot ulcers or surgical site infections. These complex wounds that have shown signs of stalled healing respond well to intervention with the Adtec SteriPlas.
To learn more about our medical device and the benefits it offers to patients with wounds, surgical site infections and dermatological conditions send us an email at info@adtec.eu.com
Deutscher Wundkongress, Bremen 2019
Adtec Healthcare is excited to participate at the DEWU Deutscher Wundkongress in collaboration with other plasma medicine companies next week in Bremen.
https://www.bremer-pflegekongress.de/Teilnehmer_allgemeine_Informationen_w
The plasma medicine companies will introduce the different plasma technologies, product and clinical safety and introduce some of the clinical evidence gathered so far.
This is an exciting opportunity to learn more about gas plasma and we encourage you to attend the session to see the benefits of gas plasma in clinic practice.
Gas plasma shows promising results in the treatment of non-healing wounds
Renowned for its ability to successfully treat non-healing wounds, the Adtec SteriPlas is a must have for any dermatology and wound care departments.
This 61-year-old patient with a long-term venous ulcer was stalled from healing and present with Klebsiella oxytoca and Enterobacter cloacae. The patient went through a short treatment programme with our gas plasma medical device to achieve exceptional results. Figures (a) - (b) shows the visual changes of the ulcer throughout the short course of treatment with the Adtec SteriPlas.
At the end of the treatment programme, swabs which would normally have shown signs of bacteria were now sterile, allowing the patient to further progress into full healing.
Interested to hear more? Reach out to us at info@adtec.eu.com
Promising results for the treatment of diabetic foot ulcers using the Adtec SteriPlas
We are excited to show you a recent conference poster presented at the BSAC Spring 2019 conference, submitted by Kettering General Hospital NHS Foundation Trust.
The poster shows the promising results of the using the Adtec SteriPlas on diabetic foot ulcers that are stalled by biofilm. The SteriPlas “is postulated as an alternative for antibiotics for patients where antibiotic therapy is difficult (due to resistance or adverse effects) or as an adjunct treatment for patients with chronic wounds including those with biofilms”.
Contact us at info@adtec.eu.com to learn more about how the Adtec SteriPlas may benefit your non-healing wound patients.
